newscontact us

TotipotentRX & ThermoGenesis Case Study Demonstrates Autologous Stem Cell Product Safely Treats Primary Heart Attack in 60 Minute Clinical Procedure

Initial Data From AMIRST Combination Product Therapy 24 Month Safety Case Study Released

LOS ANGELES and RANCHO CORDOVA, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) — TotipotentRX Corporation and ThermoGenesis Corp. (Nasdaq:KOOL), reported yesterday at the annual meeting of the American Association of Blood Banks in Denver, Colorado, a study confirming TotipotentRX’s ground-breaking acute myocardial infarction (“AMI”) combination product utilizing ThermoGenesis’ point-of-care cell processing technology for an autologous bone marrow derived stem cell therapy can be delivered safely in 60 minutes.

101413 AMI Clinical Case Study Final